RU2001114978A - N-ARILAMIDES OF ANTANILIC ACID AND THIOANTRANILIC ACID - Google Patents
N-ARILAMIDES OF ANTANILIC ACID AND THIOANTRANILIC ACIDInfo
- Publication number
- RU2001114978A RU2001114978A RU2001114978/04A RU2001114978A RU2001114978A RU 2001114978 A RU2001114978 A RU 2001114978A RU 2001114978/04 A RU2001114978/04 A RU 2001114978/04A RU 2001114978 A RU2001114978 A RU 2001114978A RU 2001114978 A RU2001114978 A RU 2001114978A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- pyridyl
- amino
- benzamide
- ness
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 75
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 43
- -1 2,1,3-benzothiadiazole -4-yl Chemical group 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 22
- 239000011780 sodium chloride Substances 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 150000001204 N-oxides Chemical class 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical group CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 125000001589 carboacyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000005493 quinolyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 3
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- 230000002194 synthesizing Effects 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- AJGLCXBDYCEVIE-UHFFFAOYSA-N 5-chloro-3-hydroxy-1H-pyridin-2-one Chemical compound OC1=CC(Cl)=CN=C1O AJGLCXBDYCEVIE-UHFFFAOYSA-N 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 102100016102 NTRK1 Human genes 0.000 claims 2
- 101700043017 NTRK1 Proteins 0.000 claims 2
- 206010038932 Retinopathy Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 150000001448 anilines Chemical class 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 230000001613 neoplastic Effects 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RGCPXQJMJGAUFW-UHFFFAOYSA-N 2-(2-pyridin-4-ylethylamino)-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCCC=2C=CN=CC=2)=C1 RGCPXQJMJGAUFW-UHFFFAOYSA-N 0.000 claims 1
- BLAFVGLBBOPRLP-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 BLAFVGLBBOPRLP-UHFFFAOYSA-N 0.000 claims 1
- CARBQIOXWBDDLK-UHFFFAOYSA-N 3-(methylamino)-2-(pyridin-4-ylmethyl)-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C=1C=NC=CC=1CC=1C(NC)=CC=CC=1C(=O)NC1=CC=CC(C(F)(F)F)=C1 CARBQIOXWBDDLK-UHFFFAOYSA-N 0.000 claims 1
- VMAQYKGITHDWKL-UHFFFAOYSA-N 5-methylimidazolidine-2,4-dione Chemical compound CC1NC(=O)NC1=O VMAQYKGITHDWKL-UHFFFAOYSA-N 0.000 claims 1
- RNOLFZACEWWIHP-UHFFFAOYSA-N 6-chloro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=CC(Cl)=CC=C21 RNOLFZACEWWIHP-UHFFFAOYSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000003638 reducing agent Substances 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
Claims (19)
где W обозначает О или S;
Х обозначает NR8;
Y обозначает CR9R10-(СН2)n, где R9 и R10 независимо друг от друга обозначают водород или (низш. )алкил и n обозначает целое число от 0 включительно и до 3 включительно; или
Y обозначает SO2;
R1 обозначает арил;
R2 обозначает моно- или бициклическую гетероарильную группу, включающую один или несколько кольцевых атомов азота при условии, что R2 не может обозначать 2-фталимидил, и в случае, когда Y обозначает SO2, не может обозначать 2,1,3-бензотиадиазол-4-ил;
любой из радикалов R3, R4, R5 и R6 независимо друг от друга обозначает Н или заместитель, отличный от водорода, и
R7 и R8 независимо друг от друга обозначают водород или (низш. )алкил; или его N-оксида или фармацевтически приемлемой соли для получения фармацевтического продукта, предназначенного для лечения неопластического заболевания, которое облегчается при ингибировании активности тирозинкиназного рецептора VEGF.1. The use of the compounds of formula I
where W is O or S;
X is NR 8 ;
Y is CR 9 R 10 - (CH 2 ) n , where R 9 and R 10 are independently hydrogen or lower alkyl and n is an integer from 0 inclusive to 3 inclusive; or
Y is SO 2 ;
R 1 is aryl;
R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms, provided that R 2 cannot denote 2-phthalimidyl, and in the case when Y is SO 2 , cannot denote 2,1,3-benzothiadiazole -4-yl;
any of the radicals R 3 , R 4 , R 5 and R 6 independently from each other means H or a substituent other than hydrogen, and
R 7 and R 8 independently of one another are hydrogen or lower alkyl; or an N-oxide thereof or a pharmaceutically acceptable salt, for the manufacture of a pharmaceutical product for the treatment of a neoplastic disease that is alleviated by inhibiting the activity of the VEGF tyrosine kinase receptor.
где r равно 0-2;
А, В, D и Е независимо друг от друга обозначают N или СН, при условии, что не более двух из этих радикалов обозначают N; предпочтительно; и
Q обозначает (низш. )алкил, гидрокси, (низш. )алкокси, (низш. )тиоалкил или галоген;
любой из радикалов R3, R4, R5 и R6 независимо друг от друга обозначает Н, фтор или (низш. )алкил; и
R7 и R8 независимо друг от друга обозначают Н или (низш. )алкил; или его N-оксид или фармацевтически приемлемая соль.7. The compound of formula I according to claim 5, in which W is O or S; X is NR 8 ; Y is CHR 9 - (CH 2 ) n , where R 9 is hydrogen or lower alkyl and n is 0-3 provided that n is not 1 when R 9 is hydrogen; or Y is SO 2 ; R 1 is phenyl, which may be unsubstituted or substituted by 1-3 substituents selected from the group consisting of amino, mono- or disubstituted amino groups, where the substituents are independently selected from the group consisting of (lower) alkyl, hydroxy (lower .) alkyl, phenyl (ness.) alkyl, (ness.) alkanoyl, benzoyl and substituted benzoyl, in which the phenyl radical is substituted by one or two substituents selected from the group consisting of nitro, amino, halogen, N- (ness.) alkylamino, N, N-di (ness.) alkylamino, hydroxy, cyano, carboxy group, (ness.) alkox icarbonyl, (ness.) alkanoyl and carbamoyl; and phenyl (ness.) alkoxycarbonyl, in which the phenyl radical is substituted by one or two substituents selected from the group consisting of nitro, amino, halogen, N- (ness.) alkylamino, N, N-di (ness.) alkylamino hydroxy, cyano, carboxy, lower alkoxycarbonyl lower alkanoyl and carbamoyl; (ness.) alkyl; substituted (ness.) alkyl, in which up to three substituents are present, independently from each other, selected from the group consisting of halogen, N- (ness.) alkylamino, N, N-di (ness.) alkylamino, N- ( ness.) alkanoylamino-, hydroxy-, cyano-, carboxy-group, (ness.) alkoxycarbonyl and phenyl (ness.) alkoxycarbonyl; hydroxy; (ness.) alkoxy; phenyl lower alkoxy; phenyloxy; halogen (ness.) alkoxy; (ness.) alkanoyloxy; benzyloxy; (ness.) alkoxycarbonyloxy; phenyl lower alkoxycarbonyloxy; nitro; cyano; carboxy group; (ness.) alkoxycarbonyl; phenyl lower alkoxycarbonyl; phenyloxycarbonyl; (ness.) alkylcarbonyl; carbamoyl; N-mono- or N, N-disubstituted carbamoyl, which is substituted on the terminal nitrogen by one or two substituents, independently from each other, selected from the group consisting of (lower) alkyl, phenyl (lower) alkyl, and hydroxy (lower .) alkyl; amidino; guanidino; mercapto; sulfo; (ness.) alkylthio; phenylthio; phenyl lower alkylthio; (ness.) alkyl phenylthio group; (ness.) alkylsulfinyl; phenylsulfinyl; phenyl lower alkylsulfinyl; (ness.) alkylphenylsulfinyl; (ness.) alkanesulfonyl; phenylsulfonyl; phenyl lower alkylsulfonyl; (ness.) alkylphenylsulfonyl; (ness.) alkenyl; (ness.) alkanoyl; halogen (ness.) alkyl mercapto group; halogen (ness.) alkylsulfonyl; dihydroxyboron (-B (OH) 2 ); and (ness.) alkylenedioxy group attached to adjacent ring carbon atoms; R 2 is imidazolyl, quinolyl, naphthyridinyl or a fragment of formula Ib or Ic
where r is 0-2;
A, B, D, and E independently represent N or CH, provided that no more than two of these radicals denote N; preferably; and
Q is (ness.) Alkyl, hydroxy, (ness.) Alkoxy, (ness.) Thioalkyl or halogen;
any of the radicals R 3 , R 4 , R 5 and R 6, independently of one another, is H, fluoro or lower alkyl; and
R 7 and R 8 are independently H and lower alkyl; or its N-oxide or a pharmaceutically acceptable salt.
2-[(4-пиридил)метил] амино-N-(4-трифторметилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-метилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(3-фтор-4-метилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-хлор-3-трифторметилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(3-хлор-5-трифторметилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-метилфенил)-6-метилбензамид; и
2-[(4-хинолил)метил] амино-N-(4-хлорметилфенил)бензамид;
или его фармацевтически приемлемая соль.14. The compound of formula I according to claim 5, selected from the group including:
2 - [(4-pyridyl) methyl] amino-N- (4-trifluoromethylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-methylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-fluoro-4-methylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-chloro-3-trifluoromethylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-chloro-5-trifluoromethylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-methylphenyl) -6-methylbenzamide; and
2 - [(4-quinolyl) methyl] amino-N- (4-chloromethylphenyl) benzamide;
or a pharmaceutically acceptable salt thereof.
2-[(4-пиридил)метил] амино-N-[3-фтор-(4-трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-фенилбензамид;
2-[(4-пиридил)метил] амино-N-[4-фтор-(3-трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3-фтор-(5-трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3,5-(бистрифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3,4-бис(трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3-метокси-(5-трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3-(1,1-диметилэтил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-(3-цианфенил)бензамид;
2-[(4-пиридил)метил] амино-N-[(3-метилтио)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-(3-ацетиламинофенил)бензамид;
2-[(4-пиридил)метил] амино-N-[3-[(аминокарбонил)амино] фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[3-(диметиламино)фенил] бензамид;
5-метокси-2-[(4-пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
3-метил-2-[(4-пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
4,5-дифтор-2-[(4-пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N'-метил-N'-[3-(трифторметил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[(3-метилсульфонил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[(3-метилсульфинил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[4-(1,1-диметилэтил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-(3-хлорфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(3-бромфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(3-метилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(3-бензоилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-[3-(аминокарбонил)фенил] бензамид;
2-[(3-пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(4-хинолинил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(5-хинолинил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(4-(2-метил)пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(4-(1,2-дигидро-2-оксо)пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[(4-хинолинил)метил] амино-N-(4-хлорфенил)бензамид;
2-[(2-имидазолил)метил] амино-N-(4-хлорфенил)бензамид;
2-[2-(4-пиридил)этил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[2-(3-пиридил)этил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[1-метил-2-(3-пиридил)этил] амино-N-[3-(трифторметил)фенил] бензамид;
2-[1-оксидо-4-пиридил)метил] амино-N-[3-(трифторметил)фенил] бензамид; и
2-[(4-пиридил)метил] метиламино-N-[3-(трифторметил)фенил] бензамид;
или его фармацевтически приемлемая соль.15. The compound of formula I according to claim 5, selected from the group including:
2 - [(4-pyridyl) methyl] amino-N- [3-fluoro- (4-trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N-phenylbenzamide;
2 - [(4-pyridyl) methyl] amino-N- [4-fluoro- (3-trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3-fluoro- (5-trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3,5- (bistrifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3,4-bis (trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3-methoxy- (5-trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3- (1,1-dimethylethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-cyanophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N - [(3-methylthio) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-acetylaminophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3 - [(aminocarbonyl) amino] phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3- (dimethylamino) phenyl] benzamide;
5-methoxy-2 - [(4-pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
3-methyl-2 - [(4-pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
4,5-difluoro-2 - [(4-pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N'-methyl-N '- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N - [(3-methylsulfonyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N - [(3-methylsulfinyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [4- (1,1-dimethylethyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-chlorophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-bromophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-methylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-benzoylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3- (aminocarbonyl) phenyl] benzamide;
2 - [(3-pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4-quinolinyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(5-quinolinyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4- (2-methyl) pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4- (1,2-dihydro-2-oxo) pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2 - [(4-quinolinyl) methyl] amino-N- (4-chlorophenyl) benzamide;
2 - [(2-imidazolyl) methyl] amino-N- (4-chlorophenyl) benzamide;
2- [2- (4-pyridyl) ethyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2- [2- (3-pyridyl) ethyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2- [1-methyl-2- (3-pyridyl) ethyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide;
2- [1-oxide-4-pyridyl) methyl] amino-N- [3- (trifluoromethyl) phenyl] benzamide; and
2 - [(4-pyridyl) methyl] methylamino-N- [3- (trifluoromethyl) phenyl] benzamide;
or a pharmaceutically acceptable salt thereof.
2-[(4-пиридил)метил] амино-N-(4-хлорнафтил)бензамид;
6-метил-2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
6-хлор-2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
3,4-метилендиокси-6-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
4,5-диметил-2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
5-хлор-2-[(4-пиридил)метил] амино-N-(4-н-пропилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-н-пропилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(7-гидроксинафтил)бензамид;
2-[(4-пиридил)метил] амино-N-(8-гидрокси-2-нафтил)бензамид;
4-хлор-2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
5-метил-2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(5,6,7,8-тетрагидронафтил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-бифенил)бензамид;
5-хлор-2-[(4-пиридил)метил] амино-N-(4-хлорфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(нафтил)бензамид;
2-[(4-пиридил)метил] амино-N-(2-нафтил)бензамид;
2-[(4-пиридил)метил] амино-N-(4-метоксифенил)бензамид;
2-[(4-пиридил)метил] амино-N-[3-(трифторметокси)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-(4-метокси-2-нафтил)бензамид;
2-[(4-пиридил)метил] амино-N-(3-бром-2-нафтил)бензамид;
2-[(4-пиридил)метил] амино-N-[4-(изопропоксикарбонил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[4-(трифторметокси)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-[4-(изопропилкарбамоил)фенил] бензамид;
2-[(4-пиридил)метил] амино-N-(3-хлор-4-метилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-(2-метилфенил)бензамид;
2-[(4-пиридил)метил] амино-N-[3-(метоксикарбонилметил)фенил] бензамид; и
2-[(4-пиридил)метил] амино-N-(4-феноксифенил)бензамид;
или его фармацевтически приемлемая соль.16. The compound of formula I according to claim 5, selected from the group including:
2 - [(4-pyridyl) methyl] amino-N- (4-chloronaphthyl) benzamide;
6-methyl-2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
6-chloro-2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
3,4-methylenedioxy-6 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
4,5-dimethyl-2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
5-chloro-2 - [(4-pyridyl) methyl] amino-N- (4-n-propylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-n-propylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (7-hydroxynaphthyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (8-hydroxy-2-naphthyl) benzamide;
4-chloro-2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
5-methyl-2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (5,6,7,8-tetrahydronaphthyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-biphenyl) benzamide;
5-chloro-2 - [(4-pyridyl) methyl] amino-N- (4-chlorophenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (naphthyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (2-naphthyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-methoxyphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3- (trifluoromethoxy) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- (4-methoxy-2-naphthyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-bromo-2-naphthyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- [4- (isopropoxycarbonyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [4- (trifluoromethoxy) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- [4- (isopropylcarbamoyl) phenyl] benzamide;
2 - [(4-pyridyl) methyl] amino-N- (3-chloro-4-methylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- (2-methylphenyl) benzamide;
2 - [(4-pyridyl) methyl] amino-N- [3- (methoxycarbonylmethyl) phenyl] benzamide; and
2 - [(4-pyridyl) methyl] amino-N- (4-phenoxyphenyl) benzamide;
or a pharmaceutically acceptable salt thereof.
а) для синтеза соединения формулы I, в котором Х обозначает NR8, где R8 обозначает водород, и Y обозначает CHR9-(CH2)n, где символы имеют значения, указанные для соединения формулы I, и остальные символы R1, R2, R3, R4, R5 и R6 имеют значения, указанные для соединения формулы I, анилиновое производное формулы II
где W, R1, R3, R4, R5, R6 и R7 имеют значения, указанные для соединения формулы I, подвергают взаимодействию с карбонильным производным формулы III,
R2-(CH2)n-C(R9)= O
где n, R2 и R9 имеют значения, указанные для соединения формулы I, в присутствии восстановителя; или
б) для синтеза соединения формулы I, в котором Y обозначает SO2, a остальные символы R1, R2, R3, R4, R5, R6, R7, W и Х имеют значения, указанные для соединения формулы I, анилиновое производное формулы II, как оно описано в варианте а) способа, подвергают взаимодействию с соединением формулы IVa
R2-Y-OH
или его реакционноспособным производным; или с соединением формулы IVb
R2-Y-Hal'
где Hal' обозначает хлор, бром или йод; или
в) для синтеза соединения формулы I, в котором Х обозначает NR8, Y обозначает СR9R10-(СH2)n, а остальные символы R1, R2, R3, R4, R5, R6, R7 и R8 имеют значения, указанные для соединения формулы I, галогенсодержащее производное формулы V
где Hal обозначает йод, бром или хлор и W, R1, R3, R4, R5, R6 и R7 имеют значения, указанные для соединения формулы I, подвергают взаимодействию с амином формулы VI
R2-(CH2)n-C(R9)(R10)-NHR8
где n, R2, R8, R9 и R10 имеют значения, указанные для соединения формулы I, в присутствии пригодного катализатора, в инертном растворителе, в присутствии апротонного основания;
причем, исходные продукты, указанные в разделах а), б) или в) также могут при необходимости иметь функциональные группы в защищенной форме и/или находиться в форме солей, при условии, если присутствует солеобразующая группа и возможна реакция с участием соединений в форме соли; удаляют любые защитные группы в защищенном производном соединений формулы I; и при необходимости превращают полученное соединение формулы I в другое соединение формулы I или в его N-оксид, превращают свободное соединение формулы I в соль, превращают полученную соль соединения формулы I в свободное соединение или в другую соль, и/или разделяют смесь изомеров соединений формулы I на индивидуальные изомеры.19. A method of obtaining a compound of formula I according to claim 5 or its N-oxide or a pharmaceutically acceptable salt, characterized in that
a) for the synthesis of a compound of formula I in which X is NR 8 , where R 8 is hydrogen, and Y is CHR 9 - (CH 2 ) n , where the symbols have the meanings indicated for the compounds of formula I and the remaining symbols R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined for the compound of formula I, an aniline derivative of formula II
where W, R 1 , R 3 , R 4 , R 5 , R 6 and R 7 have the meanings indicated for the compounds of formula I, are reacted with a carbonyl derivative of the formula III,
R 2 - (CH 2 ) n -C (R 9 ) = O
where n, R 2 and R 9 have the meanings indicated for the compounds of formula I, in the presence of a reducing agent; or
b) for the synthesis of a compound of formula I in which Y is SO 2 , and the remaining symbols R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , W and X have the meanings indicated for the compound of formula I , an aniline derivative of the formula II, as described in process variant a), is reacted with a compound of the formula IVa
R 2 -Y-OH
or its reactive derivative; or with a compound of formula IVb
R 2 -Y-Hal '
where Hal 'is chloro, bromo or iodo; or
c) for the synthesis of a compound of formula I in which X is NR 8 , Y is CR 9 R 10 - (CH 2 ) n , and the remaining symbols are R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined for the compound of formula I, a halogenated derivative of formula V
where Hal is iodine, bromine or chlorine and W, R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined for the compound of formula I, is reacted with an amine of formula VI
R 2 - (CH 2 ) n -C (R 9 ) (R 10 ) -NHR 8
where n, R 2 , R 8 , R 9 and R 10 have the meanings indicated for the compounds of formula I, in the presence of a suitable catalyst, in an inert solvent, in the presence of an aprotic base;
moreover, the starting products specified in sections a), b) or c) can also, if necessary, have functional groups in a protected form and / or in the form of salts, provided that a salt-forming group is present and a reaction involving compounds in the form of a salt is possible ; remove any protecting groups in the protected derivative of the compounds of formula I; and, if necessary, converting the obtained compound of the formula I to another compound of the formula I or its N-oxide, converting the free compound of the formula I to a salt, converting the obtained salt of the compound of the formula I to the free compound or to another salt, and / or separating the mixture of isomers of the compounds of the formula I to individual isomers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9824579.8A GB9824579D0 (en) | 1998-11-10 | 1998-11-10 | Organic compounds |
GB9824579.8 | 1998-11-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2001114978A true RU2001114978A (en) | 2003-04-20 |
RU2286338C2 RU2286338C2 (en) | 2006-10-27 |
Family
ID=10842150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001114978/04A RU2286338C2 (en) | 1998-11-10 | 1999-11-08 | Anthranilic acid and thioanthranilic acid n-arylamides |
Country Status (22)
Country | Link |
---|---|
US (4) | US6448277B2 (en) |
EP (1) | EP1129075A1 (en) |
JP (1) | JP2002529453A (en) |
KR (1) | KR100656310B1 (en) |
CN (1) | CN1152014C (en) |
AU (1) | AU758230B2 (en) |
BR (1) | BR9915210A (en) |
CA (1) | CA2346898A1 (en) |
CZ (1) | CZ299829B6 (en) |
GB (1) | GB9824579D0 (en) |
HU (1) | HUP0104188A3 (en) |
ID (1) | ID30181A (en) |
IL (1) | IL142627A0 (en) |
MX (1) | MXPA01004256A (en) |
NO (1) | NO328130B1 (en) |
NZ (1) | NZ511339A (en) |
PL (1) | PL347589A1 (en) |
RU (1) | RU2286338C2 (en) |
SK (1) | SK287259B6 (en) |
TR (1) | TR200101237T2 (en) |
WO (1) | WO2000027820A1 (en) |
ZA (2) | ZA200103290B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA013250B1 (en) * | 2004-10-22 | 2010-04-30 | Янссен Фармацевтика, Н.В. | Inhibitors of c-fms kinase |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
AU2469299A (en) * | 1998-01-23 | 1999-08-09 | Cornell Research Foundation Inc. | Purified populations of stem cells |
DE10021246A1 (en) * | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
DE10023484A1 (en) * | 2000-05-09 | 2001-11-22 | Schering Ag | New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases |
DE10023486C1 (en) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituted anthranilic acid amides and their use as medicines |
GB0029015D0 (en) | 2000-11-28 | 2001-01-10 | Univ London | Medical device |
RU2003120061A (en) * | 2000-12-07 | 2004-11-27 | Си Ви Терапьютикс, Инк. (Us) | SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS INCREASING ABC-1 COMPOUNDS AGAINST DISEASES OF THE CORONARY ARTERY OR ATHEROSCLEROSIS |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
AU2002250968C1 (en) | 2001-02-19 | 2018-01-04 | Novartis Ag | Cancer treatment |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
US7459470B2 (en) | 2001-05-08 | 2008-12-02 | Schering Ag | N-oxide anthranylamide derivatives and their use as medicaments |
ATE323694T1 (en) * | 2001-05-08 | 2006-05-15 | Schering Ag | CYANOANTHRANYLAMIDE DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS |
DE10123573B4 (en) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamide derivatives and their use as pharmaceuticals |
US20040254185A1 (en) * | 2001-05-08 | 2004-12-16 | Alexander Ernst | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
NZ529145A (en) | 2001-05-16 | 2005-07-29 | Novartis Ag | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent |
US20040247597A1 (en) * | 2001-06-20 | 2004-12-09 | Peter Carmeliet | Method of treating atherosclerosis and other inflammatory diseases |
US6858592B2 (en) | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
US7041280B2 (en) | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
EP1423012B1 (en) * | 2001-08-10 | 2007-11-14 | Imclone Systems, Inc. | Medical use of stem cells expressing vegfr-1 |
GB0126901D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
GB0126902D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
PT1487856E (en) * | 2002-03-04 | 2010-09-29 | Imclone Llc | Human antibodies specific to kdr and uses thereof |
CN101474404A (en) * | 2002-03-04 | 2009-07-08 | 伊姆克罗尼系统公司 | Combined therapy using vascular endothelial growth factor receptor antagonist for inhibiting growth of tumor |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
EP1955696B1 (en) | 2002-05-16 | 2014-05-28 | Novartis AG | Use of the EDG receptor binding agent FTY720 in cancer |
US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
JP4777648B2 (en) * | 2002-07-31 | 2011-09-21 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | VEGFR-2 and VEGFR-3 inhibitory anthranilamidopyridine |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
JP5008025B2 (en) | 2003-02-20 | 2012-08-22 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | Phenylenediamineurotensin-II receptor antagonist and CCR-9 antagonist |
US7288538B2 (en) | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
US7427683B2 (en) * | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
EP1631560A2 (en) | 2003-04-25 | 2006-03-08 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
EP2644195A1 (en) | 2003-05-19 | 2013-10-02 | Irm Llc | Immunosuppressant Compounds and Compositions |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
DE10327719A1 (en) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 and VEGFR-3 Inhibitory anthranylamide pyridones |
AU2004249256A1 (en) * | 2003-06-20 | 2004-12-29 | Alcon, Inc. | Treatment of AMD with combination of ingredients |
EP3168304A1 (en) * | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
UA89035C2 (en) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Hydroxamic acid esters and pharmaceutical use thereof |
DE102004009238A1 (en) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
US7427390B2 (en) * | 2004-03-10 | 2008-09-23 | Schering Ag | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
DE102004011720B4 (en) * | 2004-03-10 | 2008-04-03 | Bayer Schering Pharma Aktiengesellschaft | Radiohalogenated benzamide derivatives and their use in tumor diagnostics and tumor therapy |
PT1753760E (en) * | 2004-05-24 | 2008-02-12 | Hoffmann La Roche | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
AP2446A (en) * | 2004-09-22 | 2012-08-31 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and P53 |
US7645755B2 (en) | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
AU2011203515B2 (en) * | 2004-10-22 | 2013-09-12 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
US7662837B2 (en) | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
MX2007006057A (en) | 2004-11-18 | 2007-12-10 | Imclone Systems Inc | Antibodies against vascular endothelial growth factor receptor-1. |
TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
SI1863818T1 (en) * | 2005-03-23 | 2010-05-31 | Hoffmann La Roche | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US8440217B1 (en) | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
BRPI0616755A2 (en) | 2005-09-27 | 2011-06-28 | Novartis Ag | carboxyamine compounds and methods of using them |
DE602006013493D1 (en) * | 2005-09-27 | 2010-05-20 | Hoffmann La Roche | OXADIAZOLYLPYRAZOLOPYRIMIDINES AS MGLUR2 ANTAGONISTS |
US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
KR20070052207A (en) * | 2005-11-16 | 2007-05-21 | 주식회사 엘지생명과학 | Novel inhibitors of protein kinase |
AU2006314444C1 (en) | 2005-11-21 | 2018-01-04 | Novartis Ag | Neuroendocrine tumor treatment using mTOR inhibitors |
EP1955697B1 (en) * | 2005-11-30 | 2012-05-02 | Astellas Pharma Inc. | 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder |
CN102671196B (en) | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | Combinations of therapeutic agents for treating cancer |
WO2007124321A1 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
NZ572201A (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
EP2021335B1 (en) | 2006-04-20 | 2011-05-25 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
KR20090007635A (en) | 2006-05-09 | 2009-01-19 | 노파르티스 아게 | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
WO2008059513A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Compounds suitable as modulators of hdl |
EP2070908A4 (en) * | 2006-09-07 | 2011-08-10 | Univ Okayama Nat Univ Corp | Compound having benzamide skeleton and cyclooxygenase (cox-1)-selective inhibitory activity |
JP2010504933A (en) | 2006-09-29 | 2010-02-18 | ノバルティス アーゲー | Pyrazolopyrimidines as PI3K lipid kinase inhibitors |
WO2008093246A2 (en) * | 2007-02-02 | 2008-08-07 | Vegenics Limited | Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
BRPI0817483A2 (en) | 2007-10-05 | 2016-07-26 | Sanofi Aventis Deutschland | use of sulfonyl substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain |
JO3240B1 (en) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | Inhibitors of c-fms Kinase |
CN101918834B (en) * | 2008-01-07 | 2014-05-28 | 奥索临床诊断有限公司 | Calibrator/control for simultaneous assay of proteins capable of complexing with one another |
NZ588069A (en) | 2008-03-26 | 2012-06-29 | Novartis Ag | Hydroxamate-based inhibitors of deacetylases b |
EP2145873A1 (en) * | 2008-06-17 | 2010-01-20 | Commissariat A L'energie Atomique | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode |
KR20110045095A (en) | 2008-08-27 | 2011-05-03 | 레오 파마 에이/에스 | Pyridine Derivatives, a VFR-2 Receptor and Protein Tyrosine Kinase Inhibitor |
EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
BRPI0923176B8 (en) | 2008-12-18 | 2021-05-25 | Novartis Ag | crystalline form of the acid hemifumarate salt of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxy-imino]-ethyl}-2-ethyl-benzyl)-azetidine-3- carboxylic and pharmaceutical composition |
AU2009327405A1 (en) | 2008-12-18 | 2011-06-30 | Novartis Ag | New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic |
WO2010080455A1 (en) | 2008-12-18 | 2010-07-15 | Novartis Ag | New salts |
EP2391366B1 (en) | 2009-01-29 | 2012-11-28 | Novartis AG | Substituted benzimidazoles for the treatment of astrocytomas |
SI2445903T1 (en) | 2009-06-26 | 2014-07-31 | Novartis Ag | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (en) | 2009-08-12 | 2012-02-29 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation. |
GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
KR20120089463A (en) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | Heterocyclic oxime compounds |
BR112012008075A2 (en) | 2009-08-26 | 2016-03-01 | Novartis Ag | tetrasubstituted heteroaryl compounds and their use as mdm2 and / or mdm4 modulators |
CA2773661A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
EP2309271A1 (en) | 2009-09-25 | 2011-04-13 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
MY156209A (en) | 2009-11-04 | 2016-01-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful mek inhibitors |
US20120289501A1 (en) | 2009-11-25 | 2012-11-15 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
CA2781218A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (en) | 2009-12-22 | 2015-09-29 | Novartis Ag | ISOQUINOLINONES AND REPLACED QUINAZOLINONES |
DE102010014426A1 (en) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
EP2582680A1 (en) | 2010-06-17 | 2013-04-24 | Novartis AG | Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
WO2012016948A1 (en) | 2010-08-02 | 2012-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
JP2014505088A (en) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
CN103492390A (en) | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | Fluorophenyl bicyclic heteroaryl compounds |
CN103649073B (en) | 2011-04-28 | 2016-04-13 | 诺瓦提斯公司 | 17 α-hydroxylase/C 17,20-lyase inhibitor |
IN2014DN00123A (en) | 2011-06-09 | 2015-05-22 | Novartis Ag | |
US8859535B2 (en) | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
BR112014006223A8 (en) | 2011-09-15 | 2018-01-09 | Novartis Ag | 6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination |
JP5992054B2 (en) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | Pyrazolopyrrolidine compound |
JP2015503515A (en) | 2011-12-23 | 2015-02-02 | ノバルティス アーゲー | COMPOUND AND COMPOSITION FOR INHIBITING BCL2 AND BINDING PARTY INTERACTION |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CA2859873A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN104125953A (en) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | Compounds for inhibiting interaction of bcl2 with binding partners |
EP2794591A1 (en) | 2011-12-23 | 2014-10-29 | Novartis AG | Compounds for inhibiting the interaction of bcl2 with binding partners |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
MX371119B (en) | 2012-04-03 | 2020-01-17 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use. |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
JOP20180012A1 (en) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | Sulfonylation process using nonafluorobutanesulfonyl fluoride |
WO2014025675A1 (en) | 2012-08-07 | 2014-02-13 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | Combination of kinase inhibitors and uses thereof |
WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
EP2994758B1 (en) | 2013-05-08 | 2017-12-20 | Opthea Limited | Biomarkers for age-related macular degeneration (amd) |
MX2016000364A (en) | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions. |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
TW201605450A (en) | 2013-12-03 | 2016-02-16 | 諾華公司 | Combination of Mdm2 inhibitor and BRAF inhibitor and their use |
JP6526789B2 (en) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | Combination therapy |
CN106496107A (en) * | 2016-08-31 | 2017-03-15 | 浙江永宁药业股份有限公司 | VEGFR inhibitor 2 and preparation method thereof |
US20210128615A1 (en) | 2017-10-18 | 2021-05-06 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
US11602534B2 (en) | 2017-12-21 | 2023-03-14 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Pyrimidine derivative kinase inhibitors |
US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
CH504416A (en) * | 1966-12-05 | 1971-03-15 | Ciba Geigy Ag | Aromatic sulphamoyl cpd prepn. |
JPS56161362A (en) | 1980-04-03 | 1981-12-11 | Kyoto Yakuhin Kogyo Kk | Anthranilic acid derivative |
GB9405347D0 (en) | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
JPH0959236A (en) | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | Benzamide |
GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
TW523506B (en) * | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
JPH10259176A (en) | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | New amide derivative having vascularization inhibiting action and its use |
HUP0101172A3 (en) * | 1997-12-19 | 2002-12-28 | Schering Ag | Ortho-anthranilamide derivatives and their use as anti-coagulants |
CN1305454A (en) | 1998-04-20 | 2001-07-25 | 藤泽药品工业株式会社 | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase |
WO2000002851A1 (en) * | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
DE19830430A1 (en) * | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | New sulfur-substituted sulfonylamino-carboxylic acid N-arylamide derivatives useful as guanylate cyclase activators in treatment of e.g. cardiovascular disorders, asthma and diabetes |
-
1998
- 1998-11-10 GB GBGB9824579.8A patent/GB9824579D0/en not_active Ceased
-
1999
- 1999-11-08 HU HU0104188A patent/HUP0104188A3/en unknown
- 1999-11-08 KR KR1020017005866A patent/KR100656310B1/en not_active IP Right Cessation
- 1999-11-08 SK SK628-2001A patent/SK287259B6/en not_active IP Right Cessation
- 1999-11-08 IL IL14262799A patent/IL142627A0/en unknown
- 1999-11-08 TR TR2001/01237T patent/TR200101237T2/en unknown
- 1999-11-08 CA CA002346898A patent/CA2346898A1/en not_active Abandoned
- 1999-11-08 JP JP2000581000A patent/JP2002529453A/en active Pending
- 1999-11-08 AU AU13811/00A patent/AU758230B2/en not_active Ceased
- 1999-11-08 CN CNB998131083A patent/CN1152014C/en not_active Expired - Fee Related
- 1999-11-08 BR BR9915210-0A patent/BR9915210A/en not_active Application Discontinuation
- 1999-11-08 ID IDW00200101031A patent/ID30181A/en unknown
- 1999-11-08 CZ CZ20011615A patent/CZ299829B6/en not_active IP Right Cessation
- 1999-11-08 PL PL99347589A patent/PL347589A1/en not_active Application Discontinuation
- 1999-11-08 NZ NZ511339A patent/NZ511339A/en not_active IP Right Cessation
- 1999-11-08 WO PCT/EP1999/008545 patent/WO2000027820A1/en active IP Right Grant
- 1999-11-08 EP EP99971802A patent/EP1129075A1/en not_active Withdrawn
- 1999-11-08 MX MXPA01004256A patent/MXPA01004256A/en not_active IP Right Cessation
- 1999-11-08 RU RU2001114978/04A patent/RU2286338C2/en not_active IP Right Cessation
-
2001
- 2001-04-17 NO NO20011894A patent/NO328130B1/en not_active IP Right Cessation
- 2001-04-23 ZA ZA200103290A patent/ZA200103290B/en unknown
- 2001-05-07 US US09/850,434 patent/US6448277B2/en not_active Expired - Fee Related
- 2001-06-07 ZA ZA200104673A patent/ZA200104673B/en unknown
-
2002
- 2002-06-26 US US10/180,289 patent/US6878720B2/en not_active Expired - Fee Related
-
2004
- 2004-04-21 US US10/828,951 patent/US7002022B2/en not_active Expired - Fee Related
-
2005
- 2005-10-20 US US11/254,897 patent/US20060074112A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA013250B1 (en) * | 2004-10-22 | 2010-04-30 | Янссен Фармацевтика, Н.В. | Inhibitors of c-fms kinase |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001114978A (en) | N-ARILAMIDES OF ANTANILIC ACID AND THIOANTRANILIC ACID | |
JP2002529453A5 (en) | ||
EP1379507B1 (en) | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | |
RU2218328C2 (en) | Substituted phenyl derivatives, their preparing and application | |
RU2326869C2 (en) | Pyridazine 3(2h) derivatives as inhibitor of phosphodiesterase 4 (pde4), method of their preparation, pharmaceutical composition and method of treatment | |
RU2328486C2 (en) | 2-pyridone derivatives as inhibitors of neutrophil elastase | |
RU2007132161A (en) | SUBSTITUTED ARYLAMINES AND THEIR APPLICATION AS 5-HT6-RECEPTOR MODULATORS | |
US20030105091A1 (en) | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | |
JP2000504722A (en) | IL-8 receptor antagonist | |
CA2396590A1 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
RU2001132570A (en) | Urea-substituted imidazoquinolines | |
RU97100151A (en) | DERIVATIVES OF PIPERAZINE AS ANTAGONISTS 5HT1A | |
RU2003134544A (en) | AMRIDES OF ANTRANILIC ACID, METHODS FOR PRODUCING THEM, THEIR APPLICATION AS ANTIARRHYTHMIC MEDICINES, AND ALSO CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
RU2008116314A (en) | CARBOXAMINE COMPOUNDS AND THEIR APPLICATION FOR TREATMENT OF HDAC-DEPENDENT DISEASES | |
JP2003526613A (en) | Ω-Carboxyaryl-substituted diphenylureas as RAF kinase inhibitors | |
CA2376305A1 (en) | Sulfonamide and sulfamide substituted imidazoquinolines | |
EP1616865A1 (en) | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | |
RU2006141295A (en) | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | |
BG107544A (en) | Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors | |
RU2004117543A (en) | AMRIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS AN INHIBITORS OF TYROSINKINASE RECEPTOR OF VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF) | |
RU2003131970A (en) | 4- (Phenyl-piperidine-4-ylidene-methyl) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
JP2006508090A5 (en) | ||
RU97115107A (en) | BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY | |
JP2005516903A5 (en) | ||
RU2001126547A (en) | Biphenyl derivatives |